Overview

Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (Olmesartan 20 mg/Amlodipine 5 mg/Rosuvastatin 5 or 10 mg) in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease

Status:
Unknown status

Trial end date:
2020-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of OLOMAX Tab (20/5/5mg, 20/5/10mg) in Hypertension Patients with Low-Intermediate Risk for Cardiovascular Disease.

Phase:

Phase 4

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Amlodipine
Olmesartan
Olmesartan Medoxomil
Rosuvastatin Calcium